DSGN Design Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DSGN

Price (delayed)

$3.72

Market cap

$210.16M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.19

Enterprise value

$191.29M

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on ...

Highlights
DSGN's debt is down by 24% year-on-year and by 7% since the previous quarter
The quick ratio has grown by 25% from the previous quarter but it has contracted by 4.5% YoY
The EPS rose by 8% since the previous quarter but it has declined by 4.4% year-on-year
Design Therapeutics's equity has decreased by 15% YoY and by 2.6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.designtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of DSGN
Market
Shares outstanding
56.49M
Market cap
$210.16M
Enterprise value
$191.29M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.75
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$66.86M
EBITDA
-$66.29M
Free cash flow
-$58.82M
Per share
EPS
-$1.19
Free cash flow per share
-$1.05
Book value per share
$4.96
Revenue per share
$0
TBVPS
$5.17
Balance sheet
Total assets
$289.64M
Total liabilities
$11.96M
Debt
$2.33M
Equity
$277.69M
Working capital
$274.96M
Liquidity
Debt to equity
0.01
Current ratio
29.58
Quick ratio
29.29
Net debt/EBITDA
0.28
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-21.8%
Return on equity
-22.8%
Return on invested capital
-24.6%
Return on capital employed
-23.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

DSGN stock price

How has the Design Therapeutics stock price performed over time
Intraday
1.92%
1 week
-1.59%
1 month
0.54%
1 year
-48.26%
YTD
40.38%
QTD
-7.69%

Financial performance

How have Design Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$78.19M
Net income
-$66.86M
Gross margin
N/A
Net margin
N/A
DSGN's operating income is down by 16% year-on-year but it is up by 5% since the previous quarter
DSGN's net income is up by 8% QoQ but it is down by 6% YoY

Growth

What is Design Therapeutics's growth rate over time

Valuation

What is Design Therapeutics stock price valuation
P/E
N/A
P/B
0.75
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 8% since the previous quarter but it has declined by 4.4% year-on-year
Design Therapeutics's equity has decreased by 15% YoY and by 2.6% QoQ
DSGN's P/B is 6% below its last 4 quarters average of 0.8

Efficiency

How efficient is Design Therapeutics business performance
DSGN's ROE is down by 26% YoY but it is up by 3.8% QoQ
Design Therapeutics's ROA has decreased by 24% YoY but it has increased by 4% from the previous quarter
The company's return on invested capital rose by 8% YoY and by 3.5% QoQ

Dividends

What is DSGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DSGN.

Financial health

How did Design Therapeutics financials performed over time
The quick ratio has grown by 25% from the previous quarter but it has contracted by 4.5% YoY
DSGN's current ratio is up by 24% since the previous quarter but it is down by 4.9% year-on-year
DSGN's debt is 99% smaller than its equity
DSGN's debt is down by 24% year-on-year and by 7% since the previous quarter
Design Therapeutics's equity has decreased by 15% YoY and by 2.6% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.